ERYTECH successfully raises €30 million for expanding its therapeutic indications in oncology and accelerating its clinical developments Post author:admERY Post published:October 23, 2014 Post category:Newsroom ERYTECH announces today the successful completion of a capital increase for a total amount of €30 million. You Might Also Like ERYTECH Announces Publication of a Paper on Red-Blood Cell Characterization in High Impact Peer Reviewed Journal November 10, 2021 ERYTECH Sells U.S. Manufacturing Facility and Enters Long-Term Supply Agreement with Catalent April 25, 2022 ERYTECH to report positive initial results on the use of GRASPA® in ALL patients allergic to E. Coli and Erwinia derived asparaginases at ASH November 7, 2014
ERYTECH Announces Publication of a Paper on Red-Blood Cell Characterization in High Impact Peer Reviewed Journal November 10, 2021
ERYTECH Sells U.S. Manufacturing Facility and Enters Long-Term Supply Agreement with Catalent April 25, 2022
ERYTECH to report positive initial results on the use of GRASPA® in ALL patients allergic to E. Coli and Erwinia derived asparaginases at ASH November 7, 2014
